uniQures

Genezen said it will acquire uniQure’s (NASDAQ:QURE) commercial gene therapy operations in Lexington. Under the agreement, Genezen will enter into strategic supply agreements for uniQure’s clinical portfolio and CSL’s commercial HEMGENIX product. The deal will be partly funded by additional growth equity from Ampersand Capital Partners.Continue Reading